27/03/2008 (Agence Europe) - The European Medicines Agency (EMEA) has concluded that warnings about liver injury should be added to the product information for Tysabri (natalizumab), a medicine used to treat relapsing-remitting multiple sclerosis (MS). Doctors and patients should therefore take into account the liver injury risk associated to this medicine and foresee hepatic iodine surveillance, a press release diffused on 20 March states. (O.J.)